Fulvestrant - A novel endocrine therapy for breast cancer

Current Medicinal Chemistry

Volumn 17, Issue 10, 2010, Pages 902-914

  Johnston, S J ^a   Cheung, K L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Advanced breast cancer; Breast cancer; Endocrine therapy; Fulvestrant; Oestrogen; Oestrogen receptor; Sequencing

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; EXEMESTANE; FULVESTRANT; GOSERELIN; KI 67 ANTIGEN; MEGESTROL ACETATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTHROPATHY; BINDING COMPETITION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LOADING DRUG DOSE; NONHUMAN; POSTMENOPAUSE; RECEPTOR DOWN REGULATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINITIS; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 77950634822     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790820633     Document Type: Review

References (53)

1. De Muylder, X.; Neven, P.; Van Belle, Y. Tamoxifen and benign endometrial lesions. Eur. J. Cancer 1998, 34(4), S18-S19.
2. Love, R.; Mazess, R.; Barden, H.; Epstein, S.; Newcomb, P.; Jordan, V.; Carbone, P.; DeMets, D. Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. New Engl. J. Med. 1992, 326, 852-856
3. Love, R.; Wiebe, D.; Feyzi, J.; Newcomb, P.; Chappell, R. Effect of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment. J. Natl. Cancer Inst. 1994, 86, 1534-1539 (Pubitemid 24330218)
4. Wakeling, A. E.; Dukes, M.; Bowler, J. A potent specific pure antioestrogen with clinical potential. Cancer Res. 1991, 51, 3867-3873
5. Bowler, J.; Lilley, T. J.; Pittam, J. D.; Wakeling, A. E. Novel steroidal pure anti-oestrogens. Steroids 1989, 54, 71-99.
6. Cheung, K. L.; Robertson, J. F. R. Fulvestrant. Expert Opin. Investig. Drugs 2002, 11(2), 303-308
7. Huynh, H. T.; Pollack, M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182,780. Cancer Res. 1993, 53, 5585-5588
8. Blin, C.; L'Horset, F.; LeClere, T.; Lambert, M.; Colnot, S.; Thomasset, M.; Perret, C. Contrasting effects of tamoxifen and ICI 182,780 on oestrogen-induced cells. J. Steroid Biochem. Mol. Biol. 1995, 55, 1-7.
9. Hyder, S. M.; Chiappetta, C.; Murphy, L.; Stancel, G. M. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 1997, 57, 2547-2549
10. Fawell, S. E.; White, R.; Hoare, S.; Sydenham, M.; Page, M.; Parker, M. G. In Inhibition of oestrogen receptor-DNA binding by the "pure" anti-oestrogen ICI 164,384 appears to be mediated by impaired receptor dimerisation, Proc. Natl. Acad. Sci. USA; USA, 1990; pp. 6883-6887
11. Dauvois, S.; White, R.; Parker, M. G. The anti-oestrogen ICI 182,780 disrupts oestrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106, 1377-1388
12. Dauvois, S.; Danielian, P. S.; White, R.; Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. PNAS 1992, 89, 4037-4041
13. Robertson, J.; Erikstein, B.; Osborne, C.; Pippen, J.; Come, S.; Parker, L.; Gertler, S.; Harrison, M.; Clarke, D. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin. Pharmacokinet. 2004, 43(8), 529-538 (Pubitemid 38858305)
14. Lerner, L. In Estrogen antagonistic activity of MER-25, 1958;
15. Fed. Proc.: 1958; pp. 388.
16. Bucort, R.; Vignau, M.; Torelli, V. New biospecific adsorbents for the purification of estrogen receptor. J. Biol. Chem. 1978, 253, 8221-8228 (Pubitemid 9073721)
17. Wakeling, A. E.; Bowler, J. Steroidal pure antioestrogens. J. Endocrinol. 1987, 112, R7-R10.
18. Wakeling, A. E.; Bowler, J. ICI 182,780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 1992, 43(1-3), 173-177
19. Katzenellenbogen, B. S.; Kendra, K. L.; Norman, M. J.; Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 1987, 47, 4355-4360
20. Wakeling, A. E.; Newboult, E.; Peters, S. E. Effect of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol. 1989, 2, 225-234 (Pubitemid 19117459)
21. Stewart, A. J.; Johnson, M. D.; May, F. E. B.; Westley, B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 1990, 265, 21172-21178 (Pubitemid 120014136)
22. Robertson, J.F.R.; Nicholson, R.I.; Bundred, N.J.; Anderson, E.; Rayter, Z.; Dowsett, M.; Fox, J.N.; Gee, J.M.; Webster, A.; Wakeling, A.E.; Morris, C.; Dixon, M. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5(10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001, 61(18), 6739-6746 (Pubitemid 32896496)
23. Robertson, J. F. R.; Gutteridge, E.; Cheung, K. L.; Pinder S.; Wakeling A. Oestrogen receptor changes during treatment with fulvestrant (Faslodex). Program and Proceedings of ASCO Annual Meeting 2004, Abstract 536.
24. Horwitz, K. B.; Yoseki, Y.; McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogens. Endocrinology 1978, 103, 1742-1751 (Pubitemid 9051866)
25. Ellis, P. A.; Saccani-Jotti, G.; Clarke, R.; Johnston, S. R. D.; Anderson, E.; Howell, A.; A'Hern, R.; Salter, J.; Deltre, S.; Nicholson, R.; Robertson, J.; Smith, I. E.; Dowsett, M. Induction of apoptosis by tamoxifen and ICI 182,780 in primary breast cancer. Int. J. Cancer 1997, 72, 608-613 (Pubitemid 27356161)
26. Osborne, C. K.; Coronado-Heinsohn, E. B.; Hilsenbeck, S. G.; McCue, B. L.; Wakeling, A. E.; McClelland, R. A.; Manning, D. L.; Nicholoson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995, 87(10), 746-750
27. Robertson, J. F. R.; Howell, A.; De Friend, D. J.; Blarney, R. W.; Walton, P. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. Breast 1997, 6(4), 186-189 (Pubitemid 27470148)
28. Cheung, K. L.; Owers, R.; Howell, A.; Robertson, J. F. R. In Survival updates of a phase II study comparing long-acting ICI 182,780 (Faslodex) with megestrol acetate as second-line endocrine therapy for breast cancer, 7th Nottingham International Breast Cancer Conference, 2001; pp. 21.
29. Robertson, J. F. R.; Osborne, C. K.; Howell, A.; Jones, S. E.; Mauriac, L.; Ellis, M.; Kleeberg, U. R.; Come, S. E.; Vergote, I.; Gertler, S.; Buzdar, A.; Webster, A.; Morris, C. Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in post-menopausal women; a prospective combined analysis of two multicentre trials. Cancer 2003, 98, 229-238 (Pubitemid 36828445)
30. Mauriac, L.; Pippen, J. E.; Quaresma Albano, J.; Gertler, S. Z.; Osborne, C. K. Fulvestrant versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of post-menopausal women with visceral and non-visceral metastases: combined results from two multi-centre trials. Eur. J. Cancer 2003, 39(9), 1228-1233
31. Plotkin, D.; Lechner, J. J.; Jung, W. E.; Rosen, P. J. Tamoxifen flare in advanced breast cancer. JAMA 1978, 240, 2644-2646 (Pubitemid 9100750)
32. Assikis, V. J.; Jordan, V. C. Gynaecologic effects of tamoxifen and the association with endometrial carcinoma. Int. J. Gynaecol. Obstet. 1995, 49, 241-257
33. Van Leeuwen, F. E.; Benraadt, J.; Coebergh, J. W.; Kiemeney, L. A.; Gimbrere, C. H.; Otter, R.; Schouten, L. J.; Damhuis, R. A.; Bontenbal, M.; Diepenhorst, F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994, 343, 448-452 (Pubitemid 24059587)
34. Fisher, B.; Constantino, J. P.; Redmond, C. K.; Fisher, E. R.; Wickerham, D. L.; Cronin, W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86, 527-537 (Pubitemid 24111008)
35. Addo, S.; Yates, R. A.; Laight, A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy post-menopausal volunteers. Br. J. Cancer 2002, 87, 1354-1359 (Pubitemid 36044307)
36. Agrawal, A.; Hannon, R. A.; Cheung, K. L.; Eastell, R.; Robertson, J. F. R. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. Breast 2009, 18, 204-207
37. Buzdar, A.; Robertson, J. F. R.; Eiermann, W.; Nabholtz, J. M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002, 95, 2006-2016
38. Donnellan, P. P.; Douglas, S. L.; Cameron, D. A.; Leonard, R. C. Aromatase inhibitors and arthralgia. J. Clin. Oncol. 2001, 18, 1399-1411
39. Dombernowsky, P.; Smith, I.; Falkson, G.; Leonard, R.; Panasci, L.; Bellmunt, J.; Bezwoda, W.; Gardin, G.; Gudgeon, A.; Morgan, M.; Fornasiero, A.; Hoffmann, W.; Michel, J.; Hatschek, T.; Tjabbes, T.; Chaudri, H.; Hornberger, U.; Trunet, P. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 1998, 16, 453-461
40. Chia, S.; Gradishar, W.; Mauriac, L.; Bines, J.; Amant, F.; Federico, M.; Fein, L.; Romieu, G.; Buzdar, A.; Robertson, J. F. R.; Brufsky, A.; Possinger, K.; Rennie, P.; Sapunar, F.; Lowe, E.; Piccart, M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 2008, 26(10), 1664-1670
41. Howell, A.; Robertson, J. F. R.; Quaresma Albano, J.; Aschermannova, A.; Mauriac, L.; Kleeberg, U. R.; Vergote, I.; Erikstein, B.; Webster, A.; Morris, C. Fulvestrant, formerly ICI 182,780, is at least as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20(16), 3396-3403
42. Jones, S.; Vogel, C.; Arkhipov, A.; Fehrenbacker, L.; Eisenberg, P.; Cooper, B.; Honig, S.; Polli, A.; Whaley, F.; Di Salle, E.; Tiffany, J.; Consonni, A.; Miller, L. Multi-centre, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J. Clin. Oncol. 1999, 17(11), 3418-3425
43. Tang, J.; Rampaul, R.; Cheung, K.L. The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma. World J. Surg. Oncol. 2008, 6, 128..
44. Cheung, K. Endocrine therapy for breast cancer: an overview. Breast 2007, 16, 327-343 (Pubitemid 47109203)
45. Lonning, P.; Bajetta, E.; Murray, R.; Tubiana-Hulin, M.; Eisenberg, P.; Mickiewicz, E.; Celio, L.; Pitt, P.; Mita, M.; Aaronson, N.; Fowst, C.; Arkhipov, A.; Di Salle, E.; Polli, A.; Massimini, G. Activity of exemestane in metastatic breast cancer after failure of non-steroidal aromatase inhibitors: a phase II trial. J. Clin. Oncol. 2000, 18(11), 2234-2244 (Pubitemid 30350215)
46. Howell, A.; Robertson, J. F. R.; Abram, P.; Lichinitser, M. R.; Elledge, R.; Bajetta, E.; Watanabe, T.; Morris, C.; Webster, A.; Dimery, I.; al, e. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in post-menopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 2004, 22, 1605-1613
47. Cheung, K.; Owers, R.; Robertson, J. Endocrine response after prior treatment with fulvestrant for postmenopausal women with advanced breast cancer - experience from a single centre. Endocrine-Related Cancer 2006, 13, 251-255
48. Robertson, J. F. R.; Llombart-Cussac, A.; Rolski, J.; Feltl, D.; Dewar, J.; Macpherson, E.; Lindemann, J.; Ellis, M. J. Activity of Fulvestrant 500 mg versus Anastrozole 1 mg as first line treatment for advanced breast cancer: Results from the FIRST study. J. Clin. Oncol. 2009, 27(27), 4530-4535
49. Robertson, J. F. R. Fulvestrant - how to make a good drug better. Oncologist 2007, 12, 774-784
50. Di Leo, A.; Jerusalem, G.; Petruzelka, L.; Torres, R.; Bondarenko, I.; Khasanov R.; Verhoeven, D.; Pedrini, J.; Lichinitser, M.; Pendergrass, K.; Garnett, S.; Lindemann, J. P. O.; Sapunar, F.; Martin, M. CONFIRM: A Phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500 mg in post-menopausal women with estrogen receptor-positive advanced breast cancer. Cancer Res., 2009, 69(24), 491.
51. Steger, G.; Bartsch, R.; Wenzel, C.; Hussain, D.; Sevelda, U.; Pluschnig, R.; Mader, R.; Zielinski, C. C. Fulvestrant and goserelin in premenopausal women with advanced, hormone-sensitive breast cancer - A pilot study. J. Clin. Oncol. 2005, 23(16S), 708.
52. Agrawal, A.; Cheung, K. L.; Robertson, J. F. R. Fulvestrant in advanced Male Breast Cancer. Breast Cancer Res. Treat. 2007, 101, 123. (Pubitemid 47555327)
53. Giordano, S. H.; Buzdar, A. U.; Hortobagyi, G. N. Breast cancer in men. Ann. Intern. Med. 2002, 137(8), 678-687